Anti-Alzheimers activity and molecular mechanism of albumin-derived peptides against AChE and BChE

2018 ◽  
Vol 9 (2) ◽  
pp. 1173-1178 ◽  
Author(s):  
Zhipeng Yu ◽  
Sijia Wu ◽  
Wenzhu Zhao ◽  
Long Ding ◽  
Yue Fan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Global Health ◽  
Elderly People ◽  
Molecular Mechanism ◽  
Health Issue ◽  
Global Health Issue

Alzheimer's disease (AD) is a global health issue affecting millions of elderly people worldwide.

Nutritional Recommendation for COVID-19

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 753-757
Author(s):  
Anagha Gulhane ◽  
Shamli Hiware
Keyword(s):  
Immune System ◽  
Global Health ◽  
Infectious Diseases ◽  
Immune Function ◽  
The Body ◽  
Health Issue ◽  
System Quality ◽  
Life Phase ◽  
Global Health Issue ◽  
Nutritional Recommendation

It is the most unreliable truth that anybody can get infected by the COVID-19, and nobody can escape from the danger of getting tainted by the virus. Yet, the line of hope is that anyone and everyone can boost their resistance, thus avoid the risk of getting affected by the illness. The immunity of humans pulls down as they grow older. If their immune system is robust, them falling sick is feeble. If their resistance is weak, them getting ill is sound. Several factors affect the immune system and its ability, including its nourishment. A two-way connection between nutrition, infection and immunity presents. Changes in one part will affect the others part in our body that's the nature's rule. Well defined immune system quality which is present between each life phase may influence the type, generality and the degree of infections. At the same time, low nutrition to the body will decrease the immune function and expose the body to the danger of getting infected by infectious diseases. Different quantity of micronutrients is required for increasing the immunity power of our body. Generally the vitamins A,C,D,E,B2,B6,B12, iron, zinc and selenium.The deficiencies of micronutrients are acknowledged as a global health issue, and also low nutrition makes it prone to establishes the infections in the body.

Molecular Mechanism of Amyloidogenicity and Neurotoxicity of a Pro-aggregated Tau Mutant in the Presence of Histidine Tautomerism via Replica-Exchange Simulation.

2021 ◽  
Author(s):  
Sompriya Chatterjee ◽  
Abbas Salimi ◽  
Jin Yong Lee
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Mechanism ◽  
Replica Exchange

The accumulation of ΔK280 tau mutant resulting in neurotoxic oligomeric aggregates is an important but yet mysterious procedure in Alzheimer’s disease (AD) development. Recently, we proposed a histidine tautomerization hypothesis...

scholarly journals Special Issue “Oral Health and Systemic Diseases”

2020 ◽  
Vol 9 (10) ◽  
pp. 3156
Author(s):  
Gerhard Schmalz ◽  
Dirk Ziebolz
Keyword(s):  
Oral Health ◽  
Global Health ◽  
Oral Cavity ◽  
Health Issue ◽  
Systemic Diseases ◽  
Special Issue ◽  
Global Health Issue

With an enormous prevalence worldwide, diseases of the oral cavity and respective tissues are a highly relevant global health issue [...]

P4-129: Alzheimer's disease: Molecular mechanism of anesthetics induced ABETA peptide oligomerization using spectroscopy

2006 ◽  
Vol 2 ◽  
pp. S553-S554
Author(s):  
Pravat K. Mandal ◽  
Jay W. Pettegrew ◽  
K. Panchalingam ◽  
Ratna Mandal
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Mechanism ◽  
Abeta Peptide

CLINICAL AND COST-EFFECTIVENESS OF DONEPEZIL, RIVASTIGMINE, AND GALANTAMINE FOR ALZHEIMER'S DISEASE

2002 ◽  
Vol 18 (3) ◽  
pp. 497-507 ◽  
Author(s):  
Andrew Clegg ◽  
Jackie Bryant ◽  
Tricia Nicholson ◽  
Linda McIntyre ◽  
Sofie De Broe ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cost Effectiveness ◽  
Global Health ◽  
Cochrane Library ◽  
The Impact ◽  
Health Cognition ◽  
Economic Studies

Objectives: Systematic review of the clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for people suffering from Alzheimer's disease.Methods: Sixteen electronic databases (including MEDLINE, the Cochrane Library, and Embase) and bibliographies of related papers were searched for published/unpublished English language studies, and experts and pharmaceutical companies were consulted for additional information. Randomized controlled trials (RCTs) and economic studies were selected. Clinical effectiveness was assessed on measurement scales assessing progression of Alzheimer's disease on the person's global health, cognition, functional ability, behavior and mood, and quality of life. Cost-effectiveness was presented as incremental cost per year spent in a nonsevere state (by Mini Mental Health State Examination) or quality-adjusted life-year.Results: Twelve of 15 RCTs included were judged to be of good quality. Although donepezil had beneficial effects in Alzheimer's patients on global health and cognition, rivastigmine on global health, and galantamine on global health, cognition, and functional scales, these improvements were small and may not be clinically significant. Measures of quality of life and behavior and mood were rarely assessed. Adverse effects were usually mild and transient. Cost-effectiveness base case estimates ranged from £2,415 savings to £49,476 additional cost (1997 prices) per unit of effect for donepezil and a small savings for rivastigmine. Estimates were not considered robust or generalizable.Conclusions: Donepezil, rivastigmine, and galantamine appear to have some clinical effect for people with Alzheimer's disease, although the extent to which these translate into real differences in everyday life remains unclear. Due to the nature of current economic studies, cost-effectiveness remains uncertain and the impact on different care sectors has been inadequately investigated. Further research is needed to establish the actual benefits of acetylcholinesterase inhibitors (AChEls) for people with Alzheimer's disease and their caregivers, the relationship of these changes to clinical management, and careful prospective evaluation of resource and budgetary consequences.

scholarly journals The health of elderly people bearing Alzheimer’s disease: an integrative review / Saúde do idoso com doença de Alzheimer: revisão integrativa

2018 ◽  
Vol 10 (4) ◽  
pp. 941
Author(s):  
Hemmily Nóbrega Ventura ◽  
Leila De Cássia Tavares da Fonseca ◽  
Bruno César Fernandes Borges ◽  
Jéssica Yasmine Lacerda Nóbrega ◽  
Herbert Nóbrega Ventura ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Elderly People ◽  
Integrative Review

Objetivo: Verificar o conhecimento produzido pelos pesquisadores a respeito da saúde do idoso com Doença de Alzheimer (DA). Métodos: Revisão integrativa da literatura com levantamento bibliográfico realizado na Biblioteca Virtual em Saúde (BVS), MEDLINE e nos bancos de dados do Portal de Periódicos Capes.  Resultados: Observou-se a incipiência de artigos científicos publicados sobre a Doença de Alzheimer com enfoque na saúde da pessoa idosa. Conclusão: Verificou-se a necessidade de pesquisas para investigar a saúde do idoso em face à doença de Alzheimer que possibilitem aporte teórico na elaboração de políticas públicas de saúde mais abrangentes para os cuidados aos idosos. Descritores: Envelhecimento, Doença de Alzheimer, Autonomia pessoal, Saúde do idoso.

scholarly journals A narrative review of the effects of sugar-sweetened beverages on human health: A key global health issue

2020 ◽  
Vol 27 (1) ◽  
pp. e76-e103 ◽  
Author(s):  
Mainul Haque ◽  
Judy McKimm ◽  
Massimo Sartelli ◽  
Nandeeta Samad ◽  
Seraj Zohurul Haque ◽  
...  
Keyword(s):  
Global Health ◽  
Human Health ◽  
Narrative Review ◽  
Health Issue ◽  
Sugar Sweetened Beverages ◽  
Sweetened Beverages ◽  
Global Health Issue

scholarly journals Alzheimer’s Disease Diagnostics Must Be Globally Accessible

2021 ◽  
pp. 1-3
Author(s):  
Nicholas Clute-Reinig ◽  
Suman Jayadev ◽  
Kristoffer Rhoads ◽  
Anne-Laure Le Ny
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Global Health ◽  
Low Cost ◽  
High Income ◽  
Middle Income ◽  
Middle Income Countries ◽  
Disease Diagnostics ◽  
Low And Middle Income

Dementia and Alzheimer’s disease (AD) are global health crises, with most affected individuals living in low- or middle-income countries. While research into diagnostics and therapeutics remains focused exclusively on high-income populations, recent technological breakthroughs suggest that low-cost AD diagnostics may soon be possible. However, as this disease shifts onto those with the least financial and structural ability to shoulder its burden, it is incumbent on high-income countries to develop accessible AD healthcare. We argue that there is a scientific and ethical mandate to develop low-cost diagnostics that will not only benefit patients in low-and middle-income countries but the AD field as a whole.

Sign in / Sign up

Export Citation Format

Share Document